In This Issue
Journal: Blood Cancer Discovery (2023)

In This Issue| March 01 2023 In This Issue Author & Article Information Online ISSN: 2643-3249 Print ISSN: 2643-3230 ©2023 American Association for Cancer Research2023American Association for Cancer Research Blood Cancer Discov (2023) 4 (2): 101. https://doi.org/10.1158/2643-3230.BCD-4-2-ITI Related Content A commentary has been published: Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections A commentary has been published: Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy A commentary has been published: In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities View more A commentary has been published: Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis View less See also commentary Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record March 1 2023 Citation In This Issue. Blood Cancer Discov 1 March 2023; 4 (2): 101. https://doi.org/10.1158/2643-3230.BCD-4-2-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Analysis of neutralizing antibodies as well as cellular immune responses in myeloma patients following booster SARS-CoV-2 mRNA vaccines revealed impaired induction of variant neutralization and CD8 T-cell responses. Patients who developed breakthrough infections after booster vaccines had lower levels of live-virus neutralizing antibodies. These data illustrate current challenges with achieving protective immunity to SARS-CoV-2 in these immunocompromised patients and suggest that they should be prioritized for emerging approaches targeting variant-specific immunity. See article, p. 106. Clinical use and testing of anti-BCMA chimeric antigen receptor (CAR) T cells for the treatment of multiple myeloma (MM) has so far been restricted to advanced relapsed or refractory patients who progress following multiple prior therapies. To test whether CAR T-cell therapy is a feasible strategy as an early-line therapy while disease burden is low to potentially reduce incidence of immune-related adverse effects, Garfall et al. conducted a phase I clinical trial coadministering anti-BCMA... You do not currently have access to this content.